Cargando…

Interleukin-20 is involved in dry eye disease and is a potential therapeutic target

BACKGROUND: Dry eye disease (DED) is a common disease in ophthalmology, affecting millions of people worldwide. Recent studies have shown that inflammation is the core mechanism of DED. IL-20 is a proinflammatory cytokine involved in various inflammatory diseases. Therefore, we aimed to explore the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hsiao-Hsuan, Chen, Wei-Yu, Huang, Yi-Hsun, Hsu, Sheng-Min, Tsao, Yeou-Ping, Hsu, Yu-Hsiang, Chang, Ming-Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178884/
https://www.ncbi.nlm.nih.gov/pubmed/35681232
http://dx.doi.org/10.1186/s12929-022-00821-2
_version_ 1784723154356142080
author Wang, Hsiao-Hsuan
Chen, Wei-Yu
Huang, Yi-Hsun
Hsu, Sheng-Min
Tsao, Yeou-Ping
Hsu, Yu-Hsiang
Chang, Ming-Shi
author_facet Wang, Hsiao-Hsuan
Chen, Wei-Yu
Huang, Yi-Hsun
Hsu, Sheng-Min
Tsao, Yeou-Ping
Hsu, Yu-Hsiang
Chang, Ming-Shi
author_sort Wang, Hsiao-Hsuan
collection PubMed
description BACKGROUND: Dry eye disease (DED) is a common disease in ophthalmology, affecting millions of people worldwide. Recent studies have shown that inflammation is the core mechanism of DED. IL-20 is a proinflammatory cytokine involved in various inflammatory diseases. Therefore, we aimed to explore the role of this cytokine in the pathogenesis of DED and evaluate the therapeutic potential of the anti-IL-20 monoclonal antibody (mAb) 7E for DED treatment. METHODS: Clinical tear samples from patients with DED and non-DED controls were collected and their IL-20 protein levels were determined. We established three DED animal models to explore the role of IL-20 and the efficacy of IL-20 antibody in DED. Benzalkonium chloride (BAC)-induced over-evaporative DED, extra-orbital lacrimal gland excision (LGE)-induced aqueous tear-deficient DED, and desiccating stress (DS)-induced combined over-evaporative and aqueous tear-deficient DED animal models were established to investigate the role of IL-20. The anti-IL-20 antibody 7E was established to neutralize IL-20 activity. The effects of IL-20 or 7E on human corneal epithelial cells and macrophages under hyperosmotic stress were analyzed. 7E was topically applied to eyes to evaluate the therapeutic effects in the DED animal models. RESULTS: IL-20 was significantly upregulated in the tears of patients with DED and in the tears and corneas of DED animal models. Under hyperosmotic stress, IL-20 expression was induced via NFAT5 activation in corneal epithelial cells. 7E suppressed hyperosmotic stress-induced activation of macrophages. IL-20 induced cell death in corneal epithelial cells and 7E protected cells from hyperosmotic stress-induced cell death. Blocking IL-20 signaling with 7E protected mice from BAC-induced, LGE-induced, and DS-induced DED by reducing DED symptoms and inhibiting inflammatory responses, macrophage infiltration, apoptosis, and Th17 populations in the conjunctiva and draining lymph nodes. CONCLUSIONS: Our results demonstrated the functions of IL-20 in DED and presented a potential therapeutic option for this condition. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12929-022-00821-2.
format Online
Article
Text
id pubmed-9178884
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91788842022-06-10 Interleukin-20 is involved in dry eye disease and is a potential therapeutic target Wang, Hsiao-Hsuan Chen, Wei-Yu Huang, Yi-Hsun Hsu, Sheng-Min Tsao, Yeou-Ping Hsu, Yu-Hsiang Chang, Ming-Shi J Biomed Sci Research BACKGROUND: Dry eye disease (DED) is a common disease in ophthalmology, affecting millions of people worldwide. Recent studies have shown that inflammation is the core mechanism of DED. IL-20 is a proinflammatory cytokine involved in various inflammatory diseases. Therefore, we aimed to explore the role of this cytokine in the pathogenesis of DED and evaluate the therapeutic potential of the anti-IL-20 monoclonal antibody (mAb) 7E for DED treatment. METHODS: Clinical tear samples from patients with DED and non-DED controls were collected and their IL-20 protein levels were determined. We established three DED animal models to explore the role of IL-20 and the efficacy of IL-20 antibody in DED. Benzalkonium chloride (BAC)-induced over-evaporative DED, extra-orbital lacrimal gland excision (LGE)-induced aqueous tear-deficient DED, and desiccating stress (DS)-induced combined over-evaporative and aqueous tear-deficient DED animal models were established to investigate the role of IL-20. The anti-IL-20 antibody 7E was established to neutralize IL-20 activity. The effects of IL-20 or 7E on human corneal epithelial cells and macrophages under hyperosmotic stress were analyzed. 7E was topically applied to eyes to evaluate the therapeutic effects in the DED animal models. RESULTS: IL-20 was significantly upregulated in the tears of patients with DED and in the tears and corneas of DED animal models. Under hyperosmotic stress, IL-20 expression was induced via NFAT5 activation in corneal epithelial cells. 7E suppressed hyperosmotic stress-induced activation of macrophages. IL-20 induced cell death in corneal epithelial cells and 7E protected cells from hyperosmotic stress-induced cell death. Blocking IL-20 signaling with 7E protected mice from BAC-induced, LGE-induced, and DS-induced DED by reducing DED symptoms and inhibiting inflammatory responses, macrophage infiltration, apoptosis, and Th17 populations in the conjunctiva and draining lymph nodes. CONCLUSIONS: Our results demonstrated the functions of IL-20 in DED and presented a potential therapeutic option for this condition. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12929-022-00821-2. BioMed Central 2022-06-09 /pmc/articles/PMC9178884/ /pubmed/35681232 http://dx.doi.org/10.1186/s12929-022-00821-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Hsiao-Hsuan
Chen, Wei-Yu
Huang, Yi-Hsun
Hsu, Sheng-Min
Tsao, Yeou-Ping
Hsu, Yu-Hsiang
Chang, Ming-Shi
Interleukin-20 is involved in dry eye disease and is a potential therapeutic target
title Interleukin-20 is involved in dry eye disease and is a potential therapeutic target
title_full Interleukin-20 is involved in dry eye disease and is a potential therapeutic target
title_fullStr Interleukin-20 is involved in dry eye disease and is a potential therapeutic target
title_full_unstemmed Interleukin-20 is involved in dry eye disease and is a potential therapeutic target
title_short Interleukin-20 is involved in dry eye disease and is a potential therapeutic target
title_sort interleukin-20 is involved in dry eye disease and is a potential therapeutic target
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178884/
https://www.ncbi.nlm.nih.gov/pubmed/35681232
http://dx.doi.org/10.1186/s12929-022-00821-2
work_keys_str_mv AT wanghsiaohsuan interleukin20isinvolvedindryeyediseaseandisapotentialtherapeutictarget
AT chenweiyu interleukin20isinvolvedindryeyediseaseandisapotentialtherapeutictarget
AT huangyihsun interleukin20isinvolvedindryeyediseaseandisapotentialtherapeutictarget
AT hsushengmin interleukin20isinvolvedindryeyediseaseandisapotentialtherapeutictarget
AT tsaoyeouping interleukin20isinvolvedindryeyediseaseandisapotentialtherapeutictarget
AT hsuyuhsiang interleukin20isinvolvedindryeyediseaseandisapotentialtherapeutictarget
AT changmingshi interleukin20isinvolvedindryeyediseaseandisapotentialtherapeutictarget